The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of response to gemcitabine-based neoadjuvant therapy on the outcomes of gemcitabine plus nab-paclitaxel after recurrence in pancreatic cancer.
 
Takumi Kinomoto
No Relationships to Disclose
 
Kenji Ikezawa
Speakers' Bureau - AstraZeneca; Chugai Pharma; Eisai; Guardant Health; MSD; Myriad Genetics; Nihon Servier; Taiho Pharmaceutical; TAKATA Pharmaceutical
 
Kunihito Gotoh
No Relationships to Disclose
 
Yugo Kai
No Relationships to Disclose
 
Ryoji Takada
Speakers' Bureau - AstraZeneca; Merck; Novartis
 
Takanori Masumoto
No Relationships to Disclose
 
Kana Ito
No Relationships to Disclose
 
Masaki Kawabata
No Relationships to Disclose
 
Hiroki Kishimoto
No Relationships to Disclose
 
Makiko Urabe
No Relationships to Disclose
 
Kaori Mukai
No Relationships to Disclose
 
Tasuku Nakabori
No Relationships to Disclose
 
Minoru Shigekawa
Speakers' Bureau - AstraZeneca; MSD; Novartis; SERVIER; Teijin Pharma
 
Hirofumi Akita
No Relationships to Disclose
 
Hidenori Takahashi
Honoraria - AstraZeneca; Bristol-Myers Squibb; Crownjun Kono; Daiichi Sankyo; Merck; NIHON SERVIER; NOVARTIS; ONO Pharmaceutical; Taiho Pharmaceutical; TERUMO; VIATRIS
 
Shogo Kobayashi
Research Funding - AstraZeneca
 
Kazuyoshi Ohkawa
Speakers' Bureau - AstraZeneca; Chugai Pharma; Eisai; Incyte